Loss of signal transducer and activator of transcription 1 is associated with prostate cancer recurrence

STAT1 loss has previously been implicated in cell line studies to modify prostate cancer cell growth and survival, however the clinical significance of this has not previously been established. This study investigated if STAT1 loss was associated with patient outcome measures and the phenotypic consequence of STAT1 silencing. STAT1 expression was assessed in two patient cohorts with localised (n = 78) and advanced prostate cancer at initial diagnosis (n = 39) by immunohistochemistry (IHC). Impact of STAT1 silencing on prostate cancer cells lines was assessed using Cell Death detection ELISA, TLDA gene signature apoptosis arrays, WST-1 assay, xCELLigence system, clonogenic assay, and wound healing assay. In the localised patient cohort, low expression of STAT1 was associated with shorter time to disease recurrence (3.8 vs 7.3 years, P = 0.02) and disease specific survival (6.6 vs 9.3 years, P = 0.05). In the advanced patient cohort, low expression was associated with shorter time to disease recurrence (2.0 vs 3.9 years, P = 0.001). When STAT1 was silenced in PC3 cells (AR negative) and LNCaP cells (AR positive) silencing did not influence levels of apoptosis in either cell line and had little effect on cell viability in the LNCaP cells. In contrast, STAT1 silencing in the PC3 cells resulted in a pronounced increase in cell viability (WST-1 assay: mock silenced vs STAT1 silenced, P < 0.001), clonagenicity (clonogenic assay: mock silenced vs STAT1 silenced, P < 0.001), and migration (wound healing: mock silenced vs STAT1 silenced, P < 0.001). In conclusion, loss of STAT1 may promote prostate cancer recurrence in AR negative patients via increasing cell viability

A surveillance system to assess the need for updating systematic reviews.

BackgroundSystematic reviews (SRs) can become outdated as new evidence emerges over time. Organizations that produce SRs need a surveillance method to determine when reviews are likely to require updating. This report describes the development and initial results of a surveillance system to assess SRs produced by the Agency for Healthcare Research and Quality (AHRQ) Evidence-based Practice Center (EPC) Program.MethodsTwenty-four SRs were assessed using existing methods that incorporate limited literature searches, expert opinion, and quantitative methods for the presence of signals triggering the need for updating. The system was designed to begin surveillance six months after the release of the original review, and then ceforth every six months for any review not classified as being a high priority for updating. The outcome of each round of surveillance was a classification of the SR as being low, medium or high priority for updating.ResultsTwenty-four SRs underwent surveillance at least once, and ten underwent surveillance a second time during the 18 months of the program. Two SRs were classified as high, five as medium, and 17 as low priority for updating. The time lapse between the searches conducted for the original reports and the updated searches (search time lapse - STL) ranged from 11 months to 62 months: The STL for the high priority reports were 29 months and 54 months; those for medium priority reports ranged from 19 to 62 months; and those for low priority reports ranged from 11 to 33 months. Neither the STL nor the number of new relevant articles was perfectly associated with a signal for updating. Challenges of implementing the surveillance system included determining what constituted the actual conclusions of an SR that required assessing; and sometimes poor response rates of experts.ConclusionIn this system of regular surveillance of 24 systematic reviews on a variety of clinical interventions produced by a leading organization, about 70% of reviews were determined to have a low priority for updating. Evidence suggests that the time period for surveillance is yearly rather than the six months used in this project

Exploring the Development Requirements for Virtual Reality Gait Analysis

The hip joint is highly prone to traumatic and degenerative pathologies resulting in irregular locomotion. Monitoring and treatment depend on high-end technology facilities requiring physician and patient co-location, thus limiting access to specialist monitoring and treatment for populations living in rural and remote locations. Telemedicine offers an alternative means of monitoring, negating the need for patient physical presence. In addition, emerging technologies, such as virtual reality (VR) and immersive technologies, offer potential future solutions through virtual presence, where the patient and health professional can meet in a virtual environment (a virtual clinic). To this end, a prototype asynchronous telemedicine VR gait analysis system was designed, aiming to transfer a full clinical facility within the patients’ local proximity. The proposed system employs cost-effective alternative motion capture combined with the system’s immersive 3D virtual gait analysis clinic. The user interface and the tools in the application offer health professionals asynchronous, objective, and subjective analyses. This paper investigates the requirements for the design of such a system and discusses preliminary comparative data of its performance evaluation against a high-fidelity gait analysis clinical application

Exploring the Development Requirements for Virtual Reality Gait Analysis

The hip joint is highly prone to traumatic and degenerative pathologies resulting in irregular locomotion. Monitoring and treatment depend on high-end technology facilities requiring physician and patient co-location, thus limiting access to specialist monitoring and treatment for populations living in rural and remote locations. Telemedicine offers an alternative means of monitoring, negating the need for patient physical presence. In addition, emerging technologies, such as virtual reality (VR) and immersive technologies, offer potential future solutions through virtual presence, where the patient and health professional can meet in a virtual environment (a virtual clinic). To this end, a prototype asynchronous telemedicine VR gait analysis system was designed, aiming to transfer a full clinical facility within the patients’ local proximity. The proposed system employs cost-effective alternative motion capture combined with the system’s immersive 3D virtual gait analysis clinic. The user interface and the tools in the application offer health professionals asynchronous, objective, and subjective analyses. This paper investigates the requirements for the design of such a system and discusses preliminary comparative data of its performance evaluation against a high-fidelity gait analysis clinical application

A case of Kartagener syndrome with rhinolalia clausa

Kartagener syndrome is an autosomal recessive genetic ciliary disorder comprising of a classic triad of sinusitis, situs inversus and bronchiectasis. It's the one of primary ciliary dyskinesia disorders with manifestations present from childhood. Most patients of PCD have situs inversus. We present a case of 18 year-old women with recurrent lower and upper respiratory tracts infections, and rhinolalia clausa.Pan African Medical Journal 2016; 2

Les probiotiques: Seraient-ils la nouvelle génération naturelle des cofacteurs promoteurs de croissance chez le poulet de chair ?

Growth promoter antibiotics (GPAs) play an important role in improving growth performances by preventing intestinal pathogenic bacteria proliferation such us Escherichia coli, Salmonella and clostridium. However, the large use of GPAs led to antibio-resistance and residues in both food of poultry origin (offal...) and environment which has negative effects on public health and meat quality. Thus, several clinical trials have been conducted to evaluate the effects of potential alternatives to ban GPAs’ use in poultry breeding. In fact, effects of those alternatives on gut health and growth performances, have been reported to be similar at GPAs especially ensuring intestinal microbiota balance and improving gut health and zootechnical performances. Thus, there is a need for further investigations to determine: strains, doses, synergistic combination, administration’ moment and cost of the probiotics per bird to establish appropriate protocols. The current review paper sheds light on the different aspects that define probiotics, going from their mechanism of action and their effects on zootechnical parameters and the digestive health on broilers to conclude with an overview on the economic indicators that succeed in their use and the revolutionary concept of the Ovo-feed.  Key words: GPA, probiotics, broilers, gut health, growth performancesDepuis leur apparition, les antibiotiques promoteurs de croissance (APC) ont joué un rôle crucial dans l’amélioration des performances zootechniques à travers la prévention de la prolifération des bactéries pathogènes au niveau intestinal du poulet, notamment Escherichia coli, salmonelles et clostridies. Les différentes investigations scientifiques ont prouvé que leur utilisation à grande échelle a engendré une antibio-résistance et des résidus dans l’environnement, la viande et les denrées alimentaires d’origine avicole (abats...) ce qui peut se répercuter négativement sur la santé publique et l’image de qualité de ces produits.  Par conséquent, il était primordial de trouver des alternatives potentielles aux antibiotiques promoteurs de croissance afin de bannir leur utilisation en élevage avicole. On compte parmi ces produits précédemment cités, une multitude de substances et de micro-organismes, notamment les probiotiques. En effet, ces substituts ont prouvé leur faculté à égaler les effets escomptés par un APC à savoir assurer un bon équilibre du microbiote intestinal et améliorer la santé digestive et les performances zootechniques. Ainsi, il serait très lucide d’approfondir les investigations afin de déterminer la souche, la dose, le moment d’administration, les associations synergiques avec d’autre produits alternatifs ainsi que le coût de revient par individu des probiotiques afin d’établir un protocole d’usage en fonction des effets souhaités. L’objectif de ce travail est de mettre l’accent sur les différents volets qui définissent les probiotiques et ce en allant de leur mécanisme d’action et leurs effets sur les paramètres zootechniques et la santé digestive du poulet de chair pour conclure avec un aperçu sur les indicateurs économiques qui succèdent à leur usage tout en passant par un léger préambule sur le concept révolutionnaire de l’Ovo-feeding. Mots clés : APC, probiotiques, poulet de chair, santé digestive, performances de croissance

Fundamentals of Entrepreneurship (ENT300) : Chocodeli Bar / Mohd Haziq Mohammed Kamaluddin... [et.al]

ChocoDeli is a partnership business franchise that consists of 4 shareholders which also consists of our general manager, marketing manager, financial manager and operation manager. All of our profit and losses or cost that occur will be divided according to the percentage of the shares. Partnership business is one of our strategies in making maximum profit. By sharing ideas, new strategies and solving any problem together we can achieve more efficient and effective productivity

PRACTICAL GUIDE FOR FINAL YEAR PROJECT IN SOCIAL SCIENCE 2022

Final Year Project (FYP) is a research project for undergraduates in social science. Those of you who have yet to attempt it may have an idea of what an FYP is, most probably coming from your seniors. What you may have heard were essentially subjective responses coming from personal experiences of those who have gone through it. Just like any form of subjective experiences, it tells a particular story applicable to a particular person. In this section, we present an objective perspective that has a general application. In other words, what you will discover in Part 1 is a common convention pertaining to undergraduate research as practiced in the social sciences. You will gain a factual understanding of FYP and the path that lies ahead

Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive non-alcoholic fatty liver disease indexes:Results from a large multi-center study

Background: Non-invasive tools (NIT) for non-alcoholic fatty liver disease (NAFLD) screening or diagnosis need to be thoroughly validated using liver biopsies.Purpose: To externally validate NITs designed to differentiate the presence or absence of liver steatosis as well as more advanced disease stages, to confirm fully validated indexes (n = 7 NITs), to fully validate partially validated indexes (n = 5 NITs), and to validate for the first time one new index (n = 1 NIT).Methods: This is a multi-center study from two Gastroenterology-Hepatology Departments (Greece and Australia) and one Bariatric-Metabolic Surgery Department (Italy). Overall, n = 455 serum samples of patients with biopsy-proven NAFLD (n = 374, including 237 patients with non-alcoholic steatohepatitis (NASH)) and Controls (n = 81) were recruited. A complete validation analysis was performed to differentiate the presence of NAFLD vs. Controls, NASH vs. NAFL, histological features of NASH, and fibrosis stages.Results: The index of NASH (ION) demonstrated the highest differentiation ability for the presence of NAFLD vs. Controls, with the area under the curve (AUC) being 0.894. For specific histological characterization of NASH, no NIT demonstrated adequate performance, while in the case of specific features of NASH, such as hepatocellular ballooning and lobular inflammation, ION demonstrated the best performance with AUC being close to or above 0.850. For fibrosis (F) classification, the highest AUC was reached by the aspartate aminotransferase to platelet ratio index (APRI) being ~0.850 yet only with the potential to differentiate the severe fibrosis stages (F3, F4) vs. mild or moderate fibrosis (F0–2) with an AUC > 0.900 in patients without T2DM. When we excluded patients with morbid obesity, the differentiation ability of APRI was improved, reaching AUC = 0.802 for differentiating the presence of fibrosis F2–4 vs. F0–1. The recommended by current guidelines index FIB-4 seemed to differentiate adequately between severe (i.e., F3–4) and mild or moderate fibrosis (F0–2) with an AUC = 0.820, yet this was not the case when FIB-4 was used to classify patients with fibrosis F2–4 vs. F0–1. Trying to improve the predictive value of all NITs, using Youden's methodology, to optimize the suggested cut-off points did not materially improve the results.Conclusions: The validation of currently available NITs using biopsy-proven samples provides new evidence for their ability to differentiate between specific disease stages, histological features, and, most importantly, fibrosis grading. The overall performance of the examined NITs needs to be further improved for applications in the clinic

Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive non-alcoholic fatty liver disease indexes:Results from a large multi-center study

Background: Non-invasive tools (NIT) for non-alcoholic fatty liver disease (NAFLD) screening or diagnosis need to be thoroughly validated using liver biopsies.Purpose: To externally validate NITs designed to differentiate the presence or absence of liver steatosis as well as more advanced disease stages, to confirm fully validated indexes (n = 7 NITs), to fully validate partially validated indexes (n = 5 NITs), and to validate for the first time one new index (n = 1 NIT).Methods: This is a multi-center study from two Gastroenterology-Hepatology Departments (Greece and Australia) and one Bariatric-Metabolic Surgery Department (Italy). Overall, n = 455 serum samples of patients with biopsy-proven NAFLD (n = 374, including 237 patients with non-alcoholic steatohepatitis (NASH)) and Controls (n = 81) were recruited. A complete validation analysis was performed to differentiate the presence of NAFLD vs. Controls, NASH vs. NAFL, histological features of NASH, and fibrosis stages.Results: The index of NASH (ION) demonstrated the highest differentiation ability for the presence of NAFLD vs. Controls, with the area under the curve (AUC) being 0.894. For specific histological characterization of NASH, no NIT demonstrated adequate performance, while in the case of specific features of NASH, such as hepatocellular ballooning and lobular inflammation, ION demonstrated the best performance with AUC being close to or above 0.850. For fibrosis (F) classification, the highest AUC was reached by the aspartate aminotransferase to platelet ratio index (APRI) being ~0.850 yet only with the potential to differentiate the severe fibrosis stages (F3, F4) vs. mild or moderate fibrosis (F0–2) with an AUC > 0.900 in patients without T2DM. When we excluded patients with morbid obesity, the differentiation ability of APRI was improved, reaching AUC = 0.802 for differentiating the presence of fibrosis F2–4 vs. F0–1. The recommended by current guidelines index FIB-4 seemed to differentiate adequately between severe (i.e., F3–4) and mild or moderate fibrosis (F0–2) with an AUC = 0.820, yet this was not the case when FIB-4 was used to classify patients with fibrosis F2–4 vs. F0–1. Trying to improve the predictive value of all NITs, using Youden's methodology, to optimize the suggested cut-off points did not materially improve the results.Conclusions: The validation of currently available NITs using biopsy-proven samples provides new evidence for their ability to differentiate between specific disease stages, histological features, and, most importantly, fibrosis grading. The overall performance of the examined NITs needs to be further improved for applications in the clinic